PBMCs for translational immune research

Applications

Cell & Gene Therapy

From baseline immune profiling to disease-relevant human biology

Access healthy and disease-state PBMCs from characterized donors to investigate immune responses in clinically relevant biological contexts. Healthy donor PBMCs establish a reliable baseline for immune profiling, assay development, and donor comparison studies. Disease-state PBMCs enable researchers to evaluate immune responses within biologically relevant patient populations rather than relying solely on healthy donor controls.

Using donor samples with defined autoimmune, infectious disease, or cancer backgrounds can reveal disease-associated immune phenotypes, support biomarker discovery, and provide deeper insight into therapeutic activity. This approach helps researchers generate data that more closely reflects patient biology, strengthening translational relevance from early discovery through preclinical development.

Find disease-state PBMCs

Select donor material aligned to your research question

PBMCs contain multiple immune cell populations, including lymphocytes and monocytes, making them a widely used model for evaluating immune activation, cytokine signaling, cellular responses, and therapeutic effects in primary human cells.

Healthy donor PBMCs provide a consistent baseline for assay development, control comparisons, and evaluation of donor-to-donor variability. Disease-state PBMCs add clinical context by enabling studies with samples derived from donors with defined autoimmune, infectious disease, or oncology backgrounds.

Why use disease-state PBMCs?

Study immune responses in clinically relevant donor populations
Identify disease-associated cellular phenotypes
Improve biomarker discovery and patient stratification efforts
Generate data that better reflects patient biology
Increase confidence when translating findings into clinical research

Move beyond healthy donor controls to investigate disease-associated immune phenotypes, assess therapeutic response, and strengthen translational confidence.

Need donors with specific diagnoses, demographics, biomarkers, or clinical characteristics? CellFindR™ tool helps identify donor material aligned with your study requirements, enabling faster donor selection and simplified comparison between healthy and disease-state populations.

Explore offerings with CellFindr^TM tool

Evaluating Performance of Cryopreserved PBMCs

Quality of Lonza PBMCS in comparison to competitors Download Document

Applications across discovery, translational, and preclinical research

PBMCs support a broad range of immunology workflows, from early-stage immune profiling to translational and preclinical studies. Access to both healthy and disease-state donors enables researchers to evaluate immune function, compare donor populations, investigate disease-associated biology, and assess therapeutic activity in primary human cells.

Disease-state PBMCs provide additional biological relevance by allowing immune responses to be evaluated within clinically defined patient populations, supporting stronger translational insights throughout drug discovery and development.

Disease-State PBMC Applications

Disease-associated immune profiling
Biomarker discovery and validation
Patient stratification studies
Cytokine release and inflammatory pathway analysis
Pharmacodynamic and drug-response assessment
Mechanism-of-action studies
Drug repurposing research
Translational disease modeling
PBMC-humanized disease models
Preclinical efficacy evaluation

Healthy PBMC Applications

Assay development and optimization
Baseline immune profiling
Immunogenicity and safety assessments
T-cell activation and functional studies
Cytokine release evaluation
Vaccine response research
Cell engineering and iPSC generation
PBMC-humanized mouse models
Immuno-oncology studies
Cell therapy development

Designed to support reliable translational research

Characterized
donors

Access PBMCs from donors withdefined demographic, clinical, and disease-state information to support informed donor selection.

Relevant disease models

Evaluate immune responses using samples derived from donors with defined disease backgrounds and clinically relevant biology.

Reproducible results

Reduce variability through consistent donor characterization and documented cell population data.

Stronger translational relevance

Evaluate immune responses in clinically defined donor populations to generate findings that more closely reflect patient biology and support biomarker discovery, therapeutic evaluation, and clinical decisionmaking.